Home > Cardiology > Sacubitril-valsartan in hospitalized HF patients could have benefits

Sacubitril-valsartan in hospitalized HF patients could have benefits

JAMA Cardiology
Reuters Health- 07/09/2020 - Starting treatment with sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction (HFrEF) is associated with cost savings and other benefits, according to a industry-funded cost-effectiveness analysis. "The U.S. could avert significant patient suffering and save $92 million a year if sacubitril-valsartan was initiated in all new inpatient heart-failure patients who are eligible," Dr. Thomas A. Gaziano of Brigham and Women's Hospital, Harvard Medical School, in Boston, told Reuters Health by email. Previous studies showed that sacubitril-valsartan treatment in patients with HFrEF reduces mortality and hospitalization rates and is cost-effective in outpatient populations, compared with enalapril treatment. It also appears to be safe to administer sacubitril-valsartan to hospitalized patients with acute decompensated HFrEF. Dr. Gaziano and colleagues examined whether administering sacubitril-...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on